natgillin/translations-raw huggingface dataset:
Co-administration of Stribild and rifabutin is not recommended.
Ne preporučuje se istovremena primjena Stribilda i rifabutina.
Co-administration of Stribild and sildenafil for the treatment of pulmonary arterial hypertension is contraindicated.
Istovremena primjena Stribilda i sildenafila za liječenje plućne arterijske hipertenzije je kontraindicirana.
Co-administration of Stribild and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious and/or life-threatening reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam).
Istovremena primjena Stribilda i nekih lijekova koje prvenstveno metabolizira CYP3A može rezultirati povećanim koncentracijama tih lijekova u plazmi, koje su povezane s potencijalno teškim i/ili smrtonosnim reakcijama, kao što su periferni vazospazam ili ishemija (npr. dihidroergotamin, ergotamin, ergometrin) ili miopatija, uključujući i rabdomiolizu (npr. simvastatin, lovastatin) ili dugotrajna ili povećana sedacija ili respiratorna depresija (npr. midazolam primijenjen peroralno, triazolam).
Co-administration of Stribild and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Istovremena primjena Stribilda i nekih lijekova koji induciraju CYP3A, kao što su gospina trava (Hypericum perforatum), rifampicin, karbamazepin, fenobarbital i fenitoin, može dovesti do značajno smanjenih koncentracija kobicistata i elvitegravira u plazmi, što može za posljedicu imati gubitak terapijskog učinka i razvoj rezistencije (vidjeti dio 4.3).
Co-administration of Stribild with carbamazepine, phenobarbital, or phenytoin is contraindicated (see section 4.3).
Istovremena primjena Stribilda s karbamazepinom, fenobarbitalom ili fenitoinom je kontraindicirana (vidjeti dio 4.3).
Co-administration of Stribild with medicinal products that are primarily metabolised by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of those products, which could increase or prolong their therapeutic effect and adverse reactions (see Concomitant use contraindicated and section 4.3).
Istovremena primjena Stribilda i lijekova koje prvenstveno metabolizira CYP3A ili CYP2D6, ili koji su supstrati P-gp, BCRP, OATP1B1 ili OATP1B3 može za posljedicu imati povećane koncentracije tih lijekova u plazmi, što može uzrokovati povećanje ili produljenje njihova terapijskog učinka i nuspojava (vidjeti „Kontraindicirana istodobna primjena” i dio 4.3).
Co-administration of Stribild with medicinal products that inhibit CYP3A may decrease the clearance of cobicistat, resulting in increased cobicistat plasma concentrations.
Istovremena primjena Stribilda i lijekova koji inhibiraju CYP3A može smanjiti klirens kobicistata, rezultirajući povećanim koncentracijama kobicistata u plazmi.
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and therefore should be avoided.
Istovremena primjena Stribilda i oralne kontracepcije koja sadrži progestagen umjesto norgestimata, nije ispitana te se stoga mora izbjegavati.
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and, therefore, should be avoided.
Istovremena primjena Stribilda i oralnih kontraceptiva koji sadrže progestagen umjesto norgestimata nije ispitana te se stoga ne preporučuje.
Co-administration of strong CYP3A4 inducers such as carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, and St. John’s Wort with ponatinib should be avoided, and alternatives to the CYP3A4 inducer should be sought, unless the benefit outweighs the possible risk of ponatinib underexposure.
Istovremenu primjenu snažnih CYP3A4 induktora kao što su karbamazepin, fenobarbital, fenitoin, rifabutin, rifampicin, i gospina trava s ponatinibom treba izbjegavati, te potražiti alternative CYP3A4 induktoru, osim ako su koristi veće od mogućeg rizika smanjene izloženosti ponatinibu.
Co-administration of strong CYP3A4/2C9 inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure (see section 4.5).
Istodobna primjena snažnih CYP3A4/2C9 inhibitora kod slabih metabolizatora CYP2D6 bi mogla potencijalno dovesti do više izloženosti (vidjeti dio 4.5).
Co-administration of strong CYP3A4/2C9-inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure (see section 4.5).
Istodobna primjena snažnih CYP3A4/2C9 inhibitora u slabih metabolizatora CYP2D6 bi mogla potencijalno dovesti do više izloženosti (vidjeti dio 4.5).
Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast.
Istodobna primjena s jakim induktorom enzima citokroma P450 3A4 (CYP3A4), rifampicinom, rezultirala je smanjenjem sistemske izloženosti apremilastu, što za posljedicu može imati gubitak djelotvornosti apremilasta.
Co-administration of tadalafil for
istodobno s lijekom
Co-administration of tadalafil for
kroz usta s PREZISTOM istodobno
Co-administration of telaprevir with Aptivus/ritonavir is not recommended.
Istodobna primjena telaprevira s Aptivusom/ritonavirom se ne preporučuje.
Co-administration of TELZIR/ritonavir with alfuzosin is contraindicated (see section 4.3)
Istodobna primjena lijeka Telzir/ritonavira s alfuzosinom je kontraindicirana (vidjeti dio 4.3).
Co-administration of TELZIR/ritonavir with alfuzosin is contraindicated (see section 4.3).
Telzir/ritonavira s alfuzosinom je kontraindicirana (vidjeti dio 4.3).
Co-administration of temsirolimus with rifampicin, a potent CYP3A4/5 inducer, had no significant effect on temsirolimus maximum concentration (Cmax) and area under the concentration vs. time curve (AUC)after intravenous administration, but decreased sirolimus Cmax by 65% and AUC by 56%, compared to temsirolimus treatment alone.
Istodobna primjena temsirolimusa s rifampicinom, jakim induktorom CYP3A4/5, nije imala značajnog učinka na maksimalnu koncentraciju (Cmax) i površinu ispod krivulje koncentracije tijekom vremena (AUC) temsirolimusa nakon intravenske primjene, ali je smanjila Cmax sirolimusa za 65% i AUC sirolimusa za 56%, u usporedbi s liječenjem samo temsirolimusom.
Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Istodobna primjena tenofovirdizoproksila i didanozina u dozi od 400 mg na dan bila je povezana sa značajnim smanjenjem broja CD4 stanica, vjerojatno zbog unutarstanične interakcije koja je povećala razine fosforiliranog (tj. aktivnog) didanozina.
Co-administration of tenofovir disoproxil and didanosine:
Istodobna primjena tenofovirdizoproksila i didanozina
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina u dozi od 400 mg dnevno povezana je sa značajnim smanjenjem broja CD4 stanica, čemu je mogući uzrok unutarstanična interakcija koja povećava količinu fosforiliniranog (tj. aktivnog) didanozina.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina u dozi od 400 mg na dan bila je povezana sa značajnim smanjenjem broja CD4 stanica, vjerojatno zbog unutarstanične interakcije koja je povećavala fosforilirani (tj. aktivni) didanozin.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina u dozi od 400 mg na dan bila je povezana sa značajnim smanjenjem broja CD4 stanica, vjerojatno zbog unutarstanične interakcije koja povećava količinu fosforiliranog (tj. aktivnog) didanozina.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina u dozi od 400 mg na dan povezana je sa značajnim smanjenjem broja CD4 stanica, moguće zbog intracelularne interakcije koja povećava fosforilirani (tj. aktivni) didanozin.
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4 and Table 1).
Ne preporučuje se istovremena primjena tenofovirdizoproksilfumarata i didanozina (vidjeti dio 4.4 i Tablicu 1).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4 and Table 2).
Ne preporučuje se istovremena primjena tenofovirdizoproksilfumarata i didanozina (vidjeti dio 4.4 i Tablicu 2).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4).
Ne preporučuje se istovremena primjena tenofovirdizoproksilfumarata i didanozina (vidjeti dio 4.4).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Ne preporučuje se istovremena primjena tenofovirdizoproksilfumarata i didanozina, jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina ne preporučuje se.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina dovodi do povećanja sistemske izloženosti didanozinu od 40-60%, što može povećati rizik od nuspojava povezanih s didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina povećava sistemsku izloženost didanozinu za 40-60%, što može povećati rizik od nuspojava povezanih s didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina rezultira 40-60% -tnim povećanjem sistemske izloženosti didanozinu, što može povećati rizik od nuspojava povezanih s didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Istovremena primjena tenofovirdizoproksilfumarata i didanozina rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions.
Istovremena primjena tenofovirdizoproksilfumarata i didanozina rezultira 40-60% -tnim povećanjem sistemske izloženosti didanozinu, što može povećati rizik od nuspojava povezanih s didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine:
Istovremena primjena tenofovirdizoproksilfumarata i didanozina:
Co-administration of tenofovir disoproxil fumarate with cobicistat is expected to increase tenofovir plasma concentration.
Očekuje se da će istovremena primjena tenofovirdizoproksilfumarata i kobicistata povećati koncentraciju tenofovira u plazmi.
Co-administration of tenofovir disoproxil fumarate with ledipasvir/sofosbuvir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).
Pokazalo se da istovremena primjena tenofovirdizoproksilfumarata s ledipasvirom/sofosbuvirom povećava koncentracije tenofovira u plazmi, osobito kad se primjenjuje zajedno s HIV režimom koji sadrži tenofovirdizoproksilfumarat i farmakokinetički pojačivač (ritonavir ili kobicistat).
Co-administration of tenofovir disoproxil fumarate with ledipasvir/sofosbuvir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).
Primijećeno je da istovremena primjena tenofovirdizoproksilfumarata s ledipasvirom/sofosbuvirom povećava koncentraciju tenofovira u plazmi, posebno prilikom istovremene primjene s režimom liječenja HIV-a koji sadrži tenofovirdizoproksilfumarat i farmakokinetički pojačivač (ritonavir ili kobicistat).
Co-administration of tenofovir disoproxil with ledipasvir/sofosbuvir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil and a pharmacokinetic enhancer (ritonavir or cobicistat).
Primijećeno je da istodobna primjena tenofovirdizoproksila s ledipasvirom/sofosbuvirom povećava koncentraciju tenofovira u plazmi, osobito kada se koristi istodobno s režimom za liječenje HIV-a koji sadrži tenofovirdizoproksil i farmakokinetički pojačivač (ritonavir ili kobicistat).
Co-administration of the HIV protease inhibitor indinavir (800 mg three times a day), a potent CYP 3A4 inhibitor, with vardenafil (10 mg film-coated tablets) resulted in a 16-fold increase in vardenafil AUC and a 7-fold increase in vardenafil Cmax.
Istodobna primjena inhibitora proteaze HIV-a indinavira (800 mg tri puta na dan), jakog inhibitora CYP3A4, s vardenafilom (10 mg filmom obložene tablete) rezultirala je 16-strukim povećanjem AUC vardenafila i 7-strukim povećanjem Cmax vardenafila.
Co-administration of the HIV protease inhibitor indinavir (800 mg three times a day), a potent CYP3A4 inhibitor, with vardenafil (10 mg film-coated tablet) resulted in a 16-fold increase in vardenafil AUC and a 7-fold increase in vardenafil Cmax.
Istodobna primjena inhibitora proteaze HIV-a indinavira (800 mg tri puta na dan), jakog inhibitora CYP3A4, s vardenafilom (10 mg filmom obložena tableta) rezultirala je 16-strukim povećanjem AUC vardenafila i 7-strukim povećanjem Cmax vardenafila.
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with oral sildenafil (100 mg single dose) resulted in a 300 % (4-fold) increase in sildenafil Cmax and a 1,000 % (11-fold) increase in sildenafil plasma AUC.
Istodobna primjena inhibitora HIV proteaze ritonavira, koji je vrlo snažan inhibitor citokroma P450, u stanju dinamičke ravnoteže (500 mg dva puta na dan) s peroralnim oblikom sildenafila (jedna doza od 100 mg) povećala je Cmax sildenafila za 300% (4 puta), a AUC sildenafila u plazmi za 1000% (11 puta).
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300 % (4-fold) increase in sildenafil Cmax and a 1,000 % (11-fold) increase in sildenafil plasma AUC.
Istodobna primjena inhibitora HIV proteaze ritonavira, koji je vrlo snažan inhibitor citokroma P450, u stanju dinamičke ravnoteže (500 mg dva puta na dan) sa sildenafilom (jedna doza od 100 mg) povećala je Cmax sildenafila za 300% (4 puta), a AUC sildenafila u plazmi za 1000% (11 puta).
Co-administration of the proton pump inhibitor omeprazole and PROCYSBI in vivo showed no effects on cysteamine bitartrate exposure.
Istovremena primjena inhibitora protonske pumpe omeprazola i lijeka PROCYSBI in vivo nije pokazala utjecaj na izloženost cisteamin bitartratu.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Istodobna primjena jakog inhibitora CYP1A2 fluvoksamina s pomalidomidom u prisutnosti ketokonazola povećala je izloženost pomalidomidu za 104% uz 90%-tni interval pouzdanosti [88% do 122%] u usporedbi s pomalidomidom plus ketokonazolom.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Istodobna primjena jakog inhibitora CYP1A2 fluvoksamina s pomalidomidom u prisutnosti ketokonazola povećala je izloženost pomalidomidu za 104% uz 90%-tni interval pouzdanosti [88% do 122%] u usporedbi s pomalidomidom s ketokonazolom.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Istodobna primjena jakog inhibitora CYP1A2 fluvoksamina s pomalidomidom u prisutnosti ketokonazola, povećala je srednju vrijednost izloženost pomalidomidu za 107% uz 90%-tni interval pouzdanosti [91% do 124%] u usporedbi s pomalidomidom plus ketokonazolom.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Istodobna primjena jakog inhibitora CYP1A2 fluvoksamina s pomalidomidom u prisutnosti ketokonazola, povećala je srednju vrijednost izloženost pomalidomidu za 107% uz 90%-tni interval pouzdanosti [91% do 124%] u usporedbi s pomalidomidom s ketokonazolom.
Co-administration of these antifungal agents is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Očekuje se da će istodobna primjena ovih lijekova protiv gljivica povisiti koncentracije rilpivirina (inhibicija CYP3A) i tenofoviralafenamida (inhibicija P-gp) u plazmi.
Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.
Istodobna primjena tiazidnih diuretika, uključujući hidroklorotiazid, može povećati incidenciju reakcija preosjetljivosti na alopurinol.
Co-administration of this product with other veterinary medicinal products should therefore be avoided.
Stoga treba izbjegavati istovremenu primjenu ovog veterinarsko-medicinskog proizvoda s drugim veterinarsko- medicinskim proizvodima.
Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse effects of simvastatin and should be weighed against potential benefits.
Istodobna primjena tikagrelora s dozama simvastatina koje prelaze 40 mg dnevno može uzrokovati štetne događaje uzrokovane simvastatinom, što treba odvagati u odnosu na potencijalne prednosti.
Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as co-administration may lead to a substantial increase in exposure to ticagrelor (see section 4.5).
Istodobna primjena tikagrelora s jakim inhibitorima CYP3A4 (npr. ketokonazol, klaritromicin, nefazodon, ritonavir i atazanavir) je kontraindicirana, budući da istodobna primjena može dovesti do značajnog povećanja izloženosti tikagreloru (vidjeti dio 4.5).
Co-administration of tipranavir and
lijekova u istodobnoj primjeni s
Co-administration of Tivicay with some medicines should be avoided in this population (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).
U ovoj populaciji treba izbjegavati istodobnu primjenu lijeka Tivicay s nekim lijekovima (npr. efavirenzom, nevirapinom, tipranavirom/ritonavirom ili rifampicinom).
Co-administration of tolvaptan and ketoconazole resulted in a 440% increase in area under time-concentration curve (AUC) and 248% increase in maximum observed plasma concentration (Cmax) for tolvaptan.
Istovremena primjena tolvaptana i ketokonazola imala je za posljedicu povećanje površine ispod krivulje vrijeme-koncentracija (AUC) za 440% i povećanje najveće koncentracije tolvaptana u plazmi (Cmax) za 248%.
Co-administration of tolvaptan with rifampicin reduces Cmax and AUC for tolvaptan by about 85%.
Istovremena primjena tolvaptana s rifampicinom smanjuje Cmax i AUC tolvaptana za oko 85%.
Co-administration of Triumeq and other drugs that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration.
Istodobna primjena lijeka Triumeq i drugih lijekova koji inhibiraju UGT1A1, UGT1A3, UGT1A9, CYP3A4 i/ili P-gp stoga može povećati koncentracije dolutegravira u plazmi.
Co-administration of Tybost and antiretroviral medicinal products
Istovremena primjena lijeka Tybost i antiretrovirusnih lijekova
Co-administration of Tybost and rifabutin is not recommended.
Ne preporučuje se istovremena primjena lijeka Tybost i rifabutina.
Co-administration of Tybost in patients receiving medicinal products that are substrates of these transporters may result in increased plasma concentrations of the co-administered medicinal products (see section 4.5).
Istovremena primjena lijeka Tybost u pacijenata koji primaju lijekove koji su supstrati tih transportera može za posljedicu imati povećane koncentracije istovremeno primijenjenih lijekova u plazmi (vidjeti dio 4.5).
Co-administration of Tybost with carbamazepine is contraindicated (see section 4.3).
Istovremena primjena lijeka Tybost i karbamazepina je kontraindicirana (vidjeti dio 4.3).
Co-administration of Tybost with medicinal products such as dihydroergotamine, ergotamine, ergometrine, orally administered midazolam, triazolam, amiodarone, quinidine, cisapride, pimozide, alfuzosin, simvastatin, lovastatin, and sildenafil which are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (see section 4.3).
Kontraindicirana je istovremena primjena lijeka Tybost s lijekovima poput dihidroergotamina, ergotamina, ergometrina, peroralno primijenjenog midazolama, triazolama, amiodarona, kinidina, cisaprida, pimozida, alfuzosina, simvastina, lovastatina i sildenafila čiji klirens uvelike ovisi o CYP3A i za koje su povišene koncentracije u plazmi povezane s ozbiljnim i/ili po život opasnim događajima (vidjeti dio 4.3).